The atopic dermatitis treatment ‘Dupixent’ was deemed adequate for reimbursement in children and adolescents.

Therefore, attention is now focused on whether Dupixent will become the first biological agent to be reimbursed for atopic dermatitis in children and adolescents.

The Health Insurance Review and Assessment Service announced that it had passed the agenda at the first 2023 Drug Reimbursement Evaluation Committee (DREC) meeting that had been held on the 12th.

At the meeting, DREC concluded that Sanofi-Aventis Korea’s ‘Dupixent Prefilled Inj. 200, 300mg (dupilumab, genetical recombination)’ was appropriate for reimbursement in treating 'atopic dermatitis